



General description

Bendamustine is a antineoplastic alkylating agent, used in the treatment of chronic lymphocytic leukaemia and follicular lymphoma.

INN	Bendamustine
Medicine type	Chemical agent
EML status history	First added in 2015 (TRS 994) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Added in 2015 (TRS 994) for Follicular lymphoma
Therapeutic equivalent for	
Wikipedia	Bendamustine 
DrugBank	Bendamustine 

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

